BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and apipeline of biosimilars, today announced the company hasreached licensing and supply agreements with PharmaparkLLC, for BAT 23 ...
BAT1706 is Bio-Thera Solutions’ second EMAapproved product BAT1706 is Bio-Thera Solutions’ secondproduct receiving marketing authorization from NMPA, FDA and EMA Guangzhou, China– July 30, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developinga p...
Guangzhou, China– July 25, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announced thatdosing has recently begun in an integrated Phase I / Phase III clinical studyfor BAT3306, a propo...
